This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
Main Areas of Focus
- To fill specific gaps in an investigator’s drug development plan as they advance their product toward clinical investigation
- To help investigators obtain data to get additional funding
- To help with prospective partnerships
- To help getting regulatory permission to continue
Assays that can be provided include:
- Evaluation against HIV-1, HIV-2, SIV, or SHIV
- Evaluation in established T-cell lines, peripheral blood mononuclear cells (PBMCs), or macrophages
- Evaluation against clinical isolates from different HIV subtypes
- Evaluation against drug resistant virus isolates
- Evaluation of products as single agents or in combination with other products
- Evaluation as specific inhibitors of HIV-1 Tat and Rev function
Additional tasks that can be provided under this service include:
- Generation of drug-resistant HIV isolates
- Genotypic and phenotypic characterization of drug-resistant HIV isolates
- Mode of action studies
Adaptation of an investigator’s target-based assay to a high-throughput platform, followed by screening of one or more commercially available chemical libraries in that assay.
Investigators seeking these services receive no funding from NIAID, but instead receive products or information generated by NIAID-funded contractors on their behalf.
Who Can Use This Resource
- Investigators must be conducting HIV research.
- Compounds must previously have been successfully synthesized.
- Investigators must have a defined product of known chemical structure.
- Investigators must have preliminary data to support the continued development of the product.
Products must have already been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
How To Get Started
- Follow the procedures for requesting access to DAIDS Services Program to Accelerate Drug Development
- In addition, data packages for In Vitro efficacy evaluations should address the following items:
- Proposed mode of action of product
- Assessment of product’s efficacy against the requested pathogen or a closely related pathogen, or activity in a biochemical or cell-based screen that supports the proposed mode of action
- Assessment of product’s cytotoxicity against uninfected cells